Yoon Hang “John” Kim, MD, MPH

Board-certified in Preventive Medicine and Integrative & Holistic Medicine  •  Direct Integrative Care

Ketotifen is a dual-action second-generation H1 antihistamine and partial mast cell stabilizer that has been used for decades in allergology and is increasingly positioned in functional medicine as bridge therapy for mast cell activation syndrome (MCAS). Controlled trial data are strongest in chronic urticaria and IBS with visceral hypersensitivity; case-series and consensus-panel experience support its use in multisystem MCAS, long COVID, ME/CFS, and EDS-associated dysautonomia. This article summarizes the pharmacology, reviews the human evidence base, and outlines a practical integrative protocol.

Why Revisit an Old Drug?

Mast cell activation syndrome (MCAS) is increasingly recognized as a driver of multisystem complaints in functional and integrative practice — chronic urticaria and flushing, gut hypersensitivity, neurocognitive symptoms, dysautonomia, and post-infectious syndromes including long COVID and ME/CFS. Clinicians need a wider armamentarium than the first-line second-generation H1 antihistamines alone.

Ketotifen, patented by Sandoz in the 1970s and developed initially for asthma, occupies a distinctive niche: it is both a non-competitive H1 receptor antagonist and a partial mast cell stabilizer. In the United States oral ketotifen is available only through compounding pharmacies, which has kept it under-utilized despite a substantial international evidence base. The aim of this article is to bring that evidence together in a form useful for integrative clinicians considering where ketotifen fits within a stepwise MCAS protocol.

Pharmacology: Two Complementary Actions

Ketotifen is a benzocycloheptene-based tricyclic compound with a pharmacologic profile that is genuinely dual rather than merely antihistaminic.

H1 Receptor Antagonism

As an inverse agonist of the H1 receptor, ketotifen blocks histamine-mediated pruritus, flushing, vasodilation, increased vascular permeability, bronchoconstriction, and visceral hypersensitivity. A single 1 mg oral dose produces approximately 75% brain H1 occupancy — one of the highest among clinically used antihistamines — and peripheral wheal-and-flare suppression persists for more than five days, which is a second-generation characteristic despite the compound's structural similarity to first-generation agents.

Mast Cell Stabilization

Ketotifen reduces mast cell degranulation and the release of preformed and newly synthesized mediators including histamine, tryptase, prostaglandin D2, leukotrienes (LTC4/LTD4/LTE4), TNF-α, and several chemokines. It additionally dampens the activation and migration of eosinophils, basophils, and neutrophils. The stabilizing effect is partial rather than complete, which is why ketotifen is often layered with cromolyn and mediator blockers rather than used alone in severe MCAS.

Other Pharmacologic Features

At therapeutic doses, weak anticholinergic and antiserotonergic activity is reported but generally clinically silent. The molecule is lipophilic and crosses the blood-brain barrier, which accounts for CNS penetration and the frequent early side effects of sedation and appetite stimulation. Skin-test suppression persists long after drug discontinuation, which has implications for patients undergoing allergy testing.

The Human Evidence Base

The controlled-trial literature for ketotifen spans chronic urticaria, IBS, and fibromyalgia. MCAS-specific evidence is largely observational and consensus-based, reflecting the broader reality that MCAS remains a condition without FDA-approved therapies. The evidence at present is strongest for symptom control, and more limited for disease-modifying or long-term outcomes.

Chronic Urticaria: The Most Mature Indication

Multiple controlled and open studies from the 1980s onward demonstrate efficacy of oral ketotifen in chronic idiopathic urticaria and in the physical urticarias (cold, cholinergic, dermatographic, exercise-induced). In a 2013 review in Annals of Allergy, Asthma & Immunology titled “Ketotifen in the management of chronic urticaria: resurrection of an old drug”, Sokol and colleagues at the University of Texas Medical Branch synthesized this literature and argued that ketotifen deserves renewed clinical attention, particularly in patients refractory to up-dosed second-generation H1 antihistamines. The authors note that although FDA approval for asthma was not granted, FDA staff had recommended further evaluation for chronic urticaria — a recommendation that has never been fully acted upon in robust industry-sponsored trials.

IBS with Visceral Hypersensitivity: The Best-Designed Human Trial

Klooker and colleagues (Boeckxstaens group, Amsterdam) published the methodologically strongest ketotifen trial in Gut in 2010. Sixty IBS patients underwent barostat-measured rectal sensitivity testing before and after 8 weeks of randomized treatment with ketotifen (up to 6 mg/day) or placebo, with biopsy-confirmed mast cell counts and mediator release.

Results were clinically meaningful:

• Ketotifen — but not placebo — increased the rectal discomfort threshold in patients with documented visceral hypersensitivity.
• Abdominal pain and other IBS symptoms decreased significantly, and health-related quality of life improved.
• Mast cell numbers and spontaneous rectal tryptase/histamine release were not altered by ketotifen, suggesting that clinical benefit was driven by central or remote-site mechanisms rather than by changes in rectal mast cell density.

This last point is clinically important: it supports the view that MCAS and mast cell–associated syndromes are functional disorders of mast cell behavior rather than purely proliferative diseases, and that clinical response to mast cell–directed therapy can occur without measurable change in tissue mast cell numbers.

Fibromyalgia: A Cautionary Negative Trial

Ang, Hilligoss, and Stump (Clinical Journal of Pain, 2015) conducted a phase 1 randomized controlled trial of ketotifen in fibromyalgia. Despite strong preclinical data showing reduction in mast cell degranulation and mechanical allodynia in rodent models, the trial did not demonstrate significant benefit on pain severity or functional status. This negative finding is important for calibrating expectations: when MCAS is only one of several overlapping drivers of a chronic pain syndrome, mast cell–directed monotherapy may be insufficient. In integrative practice, this argues for systematic phenotyping before committing to an extended ketotifen trial.

MCAS: Consensus Experience Rather Than Randomized Trials

The 2021 “consensus-2” MCAS diagnostic and management paper — Afrin, Molderings, and a large consortium of investigators in Diagnosis — lists ketotifen among the useful second- or third-tier mast cell–directed agents, typically layered on top of baseline H1 and H2 blockade, leukotriene receptor antagonists, and, where tolerated, low-dose aspirin. MCAS-specific RCT evidence for ketotifen remains limited, and most clinical experience is reported as case series or expert opinion. However, the biological rationale — dual H1 blockade plus partial stabilization of a population of dysfunctional mast cells — makes it a rational addition when baseline therapy provides incomplete control.

Long COVID, ME/CFS, and Dysautonomia

Afrin, Weinstock, and Molderings (International Journal of Infectious Diseases, 2020) proposed that the hyperinflammatory presentation of severe acute COVID-19 and the multisystem profile of post-COVID syndromes may be rooted in underlying mast cell activation, particularly in patients with previously unrecognized MCAS. This hypothesis has been extended to ME/CFS and to orthostatic/dysautonomic presentations, where clinical experience with ketotifen — alongside H1/H2 blockade, cromolyn, and low-histamine nutrition — suggests symptomatic benefit in a subset of patients. Randomized controlled data in these populations are still emerging.

Positioning Ketotifen Within a Functional Medicine Protocol

A defining feature of the functional medicine approach to MCAS is the insistence that pharmacologic mast cell stabilization is bridge therapy, not destination therapy. Mast cells are sentinel cells of the immune system; chronic dysregulation typically reflects chronic upstream insult. The core root-cause work in an integrative MCAS evaluation includes assessment for gut dysbiosis and SIBO, mold/mycotoxin exposure (CIRS phenotype), chronic infections (Lyme and co-infections, EBV, HHV-6, post-viral states), heavy metal and environmental chemical body burden, hormonal and HPA-axis dysregulation, and food and histamine-liberator triggers.

Ketotifen's role in this framework is to lower the clinical symptom threshold and reduce tissue injury while root-cause drivers are systematically addressed. Patients who respond well to ketotifen but relapse when it is tapered often have an unresolved upstream driver that warrants deeper evaluation.

Comparison with Other Mast Cell Agents

Practical Prescribing Considerations

Formulations

Oral ketotifen is not commercially available in the United States; only the ophthalmic formulation is OTC. Compounding pharmacies prepare capsules, tablets, and alcohol-free suspensions, typically at strengths of 0.25, 0.5, 1, 2, and 3 mg. Alcohol-free suspensions are valuable for pediatric patients, older adults with swallowing difficulty, and MCAS patients sensitive to excipients and dyes.

Starting Dose and Titration

Because sedation is the most common limiting effect and typically lessens over 2–4 weeks, most integrative protocols begin with 0.25–1 mg at bedtime, titrating upward every 1–2 weeks based on tolerability and response. Target ranges reported in the literature and in clinical practice include 1–2 mg twice daily, with selected patients requiring higher doses. Some patients achieve adequate control with bedtime dosing alone, particularly those with nocturnal histamine–driven symptoms.

Typical Layering

• Baseline scheduled second-generation H1 blockade (often up-dosed — e.g., cetirizine 10 mg every 6–12 hours as tolerated).
• H2 blockade (famotidine) for GI and systemic control.
• Leukotriene receptor antagonist (montelukast) where appropriate.
• Natural mast cell–modulating agents (quercetin, luteolin, vitamin C, adequate vitamin D).
• Cromolyn sodium for GI-predominant presentations; may be combined with ketotifen for systemic control.
• Trigger reduction: low-histamine diet trial, DAO support where clinically indicated, environmental remediation for mold and indoor air quality.

Adverse Effects and Cautions

Commonly reported adverse effects include sedation, appetite stimulation and weight gain, dry mouth, and mild dizziness. Sedation generally improves with continued use. Caution is warranted when co-prescribing with other CNS depressants, in patients with seizure disorders, and during pregnancy and lactation, where risk–benefit must be individualized. Because ketotifen suppresses skin-test reactivity for days after discontinuation, allergy skin testing should be scheduled accordingly.

Clinical Pearls

• The CNS penetration of ketotifen — usually a liability — can be therapeutic in patients with neurocognitive MCAS symptoms, sleep-onset difficulty from nocturnal histamine release, or dysautonomic symptoms that worsen at night.
• Symptom improvement without change in tissue mast cell count (as in the Klooker IBS trial) is consistent with the functional medicine view that MCAS is a disorder of mast cell behavior rather than of mast cell number, and should shape how clinicians counsel patients about realistic treatment targets.
• Phenotype-matching matters. Skin-predominant and multisystem MCAS tend to respond well to ketotifen. GI-predominant, food-triggered MCAS often benefits more from oral cromolyn as the first-line stabilizer, with ketotifen added for systemic carryover.
• Response is heterogeneous. Some patients experience substantial global improvement; others have modest or no benefit. Individualized protocols and clear reassessment intervals — typically 4–8 weeks — are essential.
• A ketotifen responder who relapses on tapering is a strong clue that an upstream driver (mold, chronic infection, dysbiosis, environmental exposure) has not yet been fully addressed.

Bottom Line

Ketotifen is a pharmacologically interesting and clinically useful tool in MCAS and mast cell–associated syndromes — not because it is disease-modifying, but because its dual H1 and partial mast cell–stabilizing action can lower the symptom threshold enough for patients to engage in the deeper root-cause work that functional medicine actually aims to accomplish. The strongest RCT evidence is in chronic urticaria and IBS with visceral hypersensitivity; the fibromyalgia trial reminds us that mast cell–directed therapy alone is not a solution to all chronic pain syndromes. Used thoughtfully, titrated slowly, and layered appropriately, ketotifen deserves a defined place in the integrative MCAS toolkit.

IMPORTANT DISCLAIMER

This article is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Ketotifen prescribing — particularly oral compounded ketotifen in the United States — requires individualized risk–benefit assessment by a qualified clinician who has reviewed the patient's full medical history, concurrent medications, and clinical context. Do not start, stop, or modify any medication based on this article. For evaluation of suspected MCAS or for consideration of a mast cell–directed therapeutic trial, consult a physician experienced in mast cell disease and functional or integrative medicine. Off-label use discussions reflect published literature and clinical experience and do not imply endorsement of any specific product, compounding pharmacy, or treatment protocol.

References

1. Sokol KC, Amar NK, Starkey J, Grant JA. Ketotifen in the management of chronic urticaria: resurrection of an old drug. Ann Allergy Asthma Immunol. 2013;111(6):433–436. doi:10.1016/j.anai.2013.10.003

2. Klooker TK, Braak B, Koopman KE, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. 2010;59(9):1213–1221. doi:10.1136/gut.2010.213108

3. Ang DC, Hilligoss J, Stump T. Mast cell stabilizer (ketotifen) in fibromyalgia: phase 1 randomized controlled clinical trial. Clin J Pain. 2015;31(9):836–842. doi:10.1097/AJP.0000000000000169

4. Afrin LB, Ackerley MB, Bluestein LS, et al. Diagnosis of mast cell activation syndrome: a global “consensus-2”. Diagnosis (Berl). 2021;8(2):137–152. doi:10.1515/dx-2020-0005

5. Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327–332. doi:10.1016/j.ijid.2020.09.016

6. Molderings GJ, Brettner S, Homann J, Afrin LB. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol. 2011;4:10. doi:10.1186/1756-8722-4-10

7. Afrin LB, Butterfield JH, Raithel M, Molderings GJ. Often seen, rarely recognized: mast cell activation disease — a guide to diagnosis and therapeutic options. Ann Med. 2016;48(3):190–201. doi:10.3109/07853890.2016.1161231

8. Grant SM, Goa KL, Fitton A, Sorkin EM. Ketotifen: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs. 1990;40(3):412–448. doi:10.2165/00003495-199040030-00006

9. Theoharides TC, Tsilioni I, Ren H. Recent advances in our understanding of mast cell activation — or should it be mast cell mediator disorders? Expert Rev Clin Immunol. 2019;15(6):639–656. doi:10.1080/1744666X.2019.1596800

10. Weiler CR. Mast cell activation syndrome: tools for diagnosis and differential diagnosis. J Allergy Clin Immunol Pract. 2020;8(2):498–506. doi:10.1016/j.jaip.2019.08.023